Prestige sumer Healthcare (US:PBH)2026-02-05 11:09Revenue Performance - Total revenues for the three months ended December 31, 2025 were $283.4 million, a decrease of $6.9 million, or 2.4%, compared to the same period in 2024[98]. - Total revenues for the nine months ended December 31, 2025 were $807.1 million, a decrease of $34.2 million, or 4.1%, compared to $841.2 million for the same period in 2024[117]. - North American OTC Healthcare segment revenues decreased by $3.2 million, or 1.4%, primarily due to declines in Eye & Ear Care, Analgesics, and Women's Health categories[100]. - North American OTC Healthcare segment revenues decreased by $32.0 million, or 4.5%, primarily due to a decline in sales in the Eye & Ear Care category[118]. - International OTC Healthcare segment revenues decreased by $3.6 million, or 7.1%, mainly due to a decline in Eye & Ear Care sales, partially offset by an increase in Women's Health[101]. - International OTC Healthcare segment revenues decreased by $2.1 million, or 1.6%, mainly due to a decrease in sales in the Eye & Ear Care category, partially offset by an increase in Women's Health sales[119]. Profitability Metrics - Gross profit for the three months ended December 31, 2025 decreased by $3.7 million, or 2.3%, compared to the same period in 2024, while gross profit margin remained constant at 55.5%[103]. - Gross profit for the nine months ended December 31, 2025 decreased by $15.2 million, or 3.3%, to $449.3 million, while gross profit margin increased to 55.7% from 55.2%[120]. - Contribution margin for the North American OTC Healthcare segment decreased by $1.9 million, or 1.9%, with a margin of 41.6% in Q3 2025, down from 41.8% in Q3 2024[108]. - Contribution margin for the North American OTC Healthcare segment decreased by $4.2 million, or 1.4%, to $285.8 million, with a margin increase to 42.1% from 40.8%[126]. - Contribution margin for the International OTC Healthcare segment decreased by $3.9 million, or 16.9%, with a margin of 40.4% in Q3 2025, down from 45.2% in Q3 2024[109]. - Contribution margin for the International OTC Healthcare segment decreased by $6.0 million, or 10.7%, to $49.8 million, with a margin decrease to 38.9% from 42.8%[127]. Expenses and Financial Position - General and administrative expenses increased by $5.0 million to $86.2 million for the nine months ended December 31, 2025, compared to $81.2 million for the same period in 2024[128]. - Interest expense, net decreased to $30.9 million for the nine months ended December 31, 2025, from $36.9 million for the same period in 2024, with average indebtedness decreasing to $1.0 billion[130]. - The provision for income taxes increased to $56.4 million for the nine months ended December 31, 2025, compared to $45.8 million for the same period in 2024, with an effective tax rate increase to 29.2% from 21.8%[132]. - Cash and cash equivalents decreased by $35.5 million to $62.4 million as of December 31, 2025, with cash provided by operating activities increasing to $214.8 million[134]. - Net cash provided by operating activities increased to $214.8 million for the nine months ended December 31, 2025, up from $189.7 million for the same period in 2024, reflecting a $25.1 million increase primarily due to working capital timing[135]. - Net cash used in investing activities rose significantly to $133.4 million for the nine months ended December 31, 2025, compared to $14.0 million for the same period in 2024, marking a $119.5 million increase primarily due to acquisitions[136]. - Net cash used in financing activities decreased to $118.0 million for the nine months ended December 31, 2025, down from $170.6 million for the same period in 2024, a reduction of $52.6 million attributed to decreased net debt repayments[137]. - As of December 31, 2025, the company had $1.0 billion in outstanding indebtedness, including $40.0 million on the 2012 ABL Revolver and a borrowing capacity of $146.4 million[138]. - The company must maintain a fixed charge ratio greater than 1.0 to 1.0 for the quarter ended December 31, 2025, and was in compliance with applicable financial covenants[140]. - The company has $400.0 million of 5.125% 2019 senior unsecured notes maturing on January 15, 2028, and $600.0 million of 3.750% 2021 senior unsecured notes maturing on April 1, 2031[141]. Strategic Developments - The acquisition of Pillar5 Pharma, Inc. was completed on December 18, 2025, funded through cash and an asset-based revolving credit facility[89]. - Economic uncertainty continues to impact supply chains, labor availability, and input costs, potentially affecting product demand and operational performance[92]. - The company has observed a shift in consumer purchasing patterns towards online channels, influencing retailer purchasing strategies[92]. - The company reported no material changes to its critical accounting policies during the nine months ended December 31, 2025[142]. - The company anticipates compliance with financial and restrictive covenants during the next twelve months based on normal operations[140]. - The company faces various risks including supply chain disruptions, competition, and dependence on third-party manufacturers[146]. - The company’s exposure to market risk has not changed materially since March 31, 2025[149].